Main Article Content
and to incorporate this complex into orally disintegrating films to enable rapid drug delivery. The prednisoloneâ€polymeric complexes were prepared using solvent evaporation and freeze drying techniques with a drugâ€polymer ratio of 1:1 using
hydroxypropyl Î²â€cyclodextrin (HP Î²â€CD), hydroxypropyl methylcellulose 4 cps, and polyvinylpyrrolidone K-30 as polymeric carriers and the parameters such as an aqueous solubility, dissolution profile, and solidâ€state characterization
using differential scanning calorimetry (DSC) of the complexes determined.The optimized complex was then incorporated into films prepared using solvent casting technique and the weight variation, thickness, solidâ€state characterization,
in vitro disintegration and dissolution profiles of the films were then determined. The highest prednisolone solubility was seen with the prednisoloneâ€HP Î²â€CD complex prepared by freeze drying (1.82 mg/mL) followed by the same complex
prepared by solvent evaporation (1.70 mg/mL). The solubilityâ€™s were significantly higher compared to prednisolone powder (0.2 mg/mL) (P < 0.05). DSC analysis of complexes revealed a reduction in area of the endothermic peak indicating
the presence of amorphous drug while in comparison, the DSC analysis of films did not show endothermic peak showing complete absence of crystalline drug. The film was thin, uniform in weight and thickness, showing rapid disintegration of
55 s with almost complete drug release within 3 min. The study revealed the incorporated drugâ€polymer complex have maintained the amorphous state and enabled rapid drug release.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
National Health Ser vices, Asthma, 2011. Available from:
(Last accessed 2011 Nov 28).
Ballinger A, Patchett S. Respiratory disease, Pocket Essentials of Clinical
Medicine. 4th ed. China: Saunders Elsevier; 2007. p. 912â€21.
Singh M, Kumar L. Continuous nebulised salbutamol and oral once a
day prednisolone in status asthmaticus. Arch Dis Child 1993;69:416â€9.
Prednisolone, 2011. Available from: http://www.medicines.org.uk.
(Last accessed 2011 Nov 28).
Storr J, Barrell E, Barry W, Lenney W, Hatcher G. Effect of a single
oral dose of prednisolone in acute childhood asthma. Lancet
Schirm E, Tobi H, de Vries TW, Choonara I, De Jongâ€van den Berg LT.
Lack of appropriate formulations of medicines for children in the
community. Acta Paediatr 2003;92:1486â€9.
Gillisen A. Patientâ€™s adherence in asthma. J Physiol Pharmacol 2007;58:205â€22.
Lemanek K. Adherence issues in the medical management of asthma.
J Pediatr Psychol 1990;15:437â€58.
Modi AC, Quittner AL. Barriers to treatment adherence for children
with cystic fibrosis and asthma: What gets in the way? J Pediatr Psychol
Lennartz P, Mielck JB. Miniâ€tabletting: Improving the compactability of
paracetamol powder mixtures. Int J Pharm 1998;173:75â€85.
Thomson SA, Tuleu C, Wong IC, Keady S, Pitt KG, Sutcliffe AG.
Minitablets: New modality to deliver medicines to preschoolâ€aged
children. Pediatrics 2009;123:e235â€8.
Aurora J, Pathak V. Oral disintegrating dosage forms: An overview. Drug
Deliv Technol 2005;5:50â€4.
Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a
model poorly waterâ€soluble drug, prednisolone, from hydroxypropyl
methylcellulose matrix tablets using (SBE) 7m-betaâ€cyclodextrin as a
solubilizing agent. J Pharm Sci 2001;90:807â€16.
Shah TJ, Amin AF, Parikh JR, Parikh RH. Process optimization
and characterization of poloxamer solid dispersions of a poorly
waterâ€soluble drug. AAPS PharmSciTech 2007;8:Article 29.
Mishra R, Amin A. Formulation and characterization of rapidly dissolving
films of cetirizine hydrochloride using pullulan as a film forming agent.
Indian J Pharm Edu Res 2011;45:71â€7.
Franco G, Latrofa M, Pantaleo A, Provenzano MR, Sanna MR, Maciocco E,
Liso EG. Physicochemical characterization and in vivo properties of
Zolpidem in solid dispersions with polyethylene glycol 4000 and 6000.
Int J Pharm 1999;184:121â€30.
Dontireddy R, Crean AM. A comparative study of sprayâ€dried and
freezeâ€dried hydrocortisone/polyvinylpyrrolidone solid dispersions.
Drug Dev Ind Pharm 2011;37:1141â€9.
Shinde SS, Patil SS, Mevekari FI, Satpute AS, An approach for solubility
enhancement: Solid dispersion. Int J Adv Pharm Sci 2010;1:299â€08.
Leuner C, Dressman J. Improving drug solubility for oral delivery using
solid dispersions. Eur J Pharm Biopharm 2000;50:47â€60.
Janssens S, de Armas HN, Roberts CJ, Van den Mooter G. Characterization
of ternary solid dispersions of itraconazole, PEG 6000, and
HPMC 2910 E5. J Pharm Sci 2008;97:2110â€20.
BÃ©ni S, SzakÃ¡cs Z, CsernÃ¡k O, Barcza L, NoszÃ¡l B. Cyclodextrin/imatinib
complexation: Binding mode and charge dependent stabilities.
Eur J Pharm Sci 2007;30:167â€74.
YÃ¡Ã±ez C, Salazar R, NÃºÃ±ezâ€Vergara LJ, Squella JA. Spectrophotometric
and electrochemical study of the inclusion complex between
betaâ€cyclodextrin and furnidipine. J Pharm Biomed Anal 2004;35:51â€6.
Moraes CM, Abrami P, de Paula E, Braga AF, Fraceto LF. Study of the
interaction between S(â€“) bupivacaine and 2â€hydroxypropylâ€betaâ€cyclodextrin.
Int J Pharm 2007;331:99â€106.
Consistency of formulated preparations. Vol. V, Appendix XII C. British
Pharmacopoeia; 2011. Available from: http://www.pharmacopoeia.
co.uk/bp2011. (Last accessed 2012 Mar 10).
ElMeshad AN, El Hagrasy AS. Characterization and optimization of
orodispersible mosapride film formulations. AAPS PharmSciTech
Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, et al.
Nicotine fast dissolving films made of maltodextrins: A feasibility study.
AAPS PharmSciTech 2010;11:1511â€7.
Jafar M, Ali S. Studies on meloxicam solid dispersion incorporated
buccal patches. Int Res J Pharm 2011;2:220â€7.
Loftsson T, FriÃ°riksdÃ³ttir H, The effect of waterâ€soluble polymers on
the aqueous solubility and complexing abilities of Î²â€cyclodextrin.
Int J Pharm 1998;163:115â€21.